Systematic analysis of synergistic proteome modulations in a drug combination of cisplatin and MLN4924.

Chemotherapeutic treatment regimens often take advantage of synergistic effects of drug combinations. Anticipating that synergistic effects on the cell biological level likely manifest on the proteome level, the analysis of proteome modulations represents an appropriate strategy to study drug combinations on a molecular level. More specifically, the detection of single proteins exhibiting synergistic abundance changes could be helpful to shed light on key molecules, which contribute in mechanisms facilitating the synergistic interaction and therefore represent potential targets for specific therapeutic approaches.

Identification of the Consistently Altered Metabolic Targets in Human Hepatocellular Carcinoma.

Background & Aims: Cancer cells rely on metabolic alterations to enhance proliferation and survival. Metabolic gene alterations that repeatedly occur in liver cancer are largely unknown. We aimed to identify metabolic genes that are consistently deregulated, and are of potential clinical significance in human hepatocellular carcinoma (HCC).

Tissue-based quantitative proteome analysis of human hepatocellular carcinoma using tandem mass tags.

Context And Objective: Human hepatocellular carcinoma (HCC) is a severe malignant disease, and accurate and reliable diagnostic markers are still needed. This study was aimed for the discovery of novel marker candidates by quantitative proteomics.

Methods And Results: Proteomic differences between HCC and nontumorous liver tissue were studied by mass spectrometry.